Jubilant Pharmova has been granted a patent for their orally administered liquid pharmaceutical compositions of eslicarbazepine. The compositions are in the form of ready-to-use suspension and suspension powder for reconstitution. These liquid compositions provide a more convenient and less cumbersome posology for patients who have difficulty swallowing tablets. The patent claims an immediate release, liquid oral pharmaceutical suspension dosage form with specific ingredients and technical attributes. The dosage form is free of xanthan gum and/or polyoxyethylene stearate and has a pH of 3.5 to 5.5. GlobalData’s report on Jubilant Pharmova gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jubilant Pharmova, graphene oxide composites was a key innovation area identified from patents. Jubilant Pharmova's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11642351B2) describes an immediate release, liquid oral pharmaceutical suspension dosage form for the treatment of partial onset seizures. The dosage form consists of eslicarbazepine or its pharmaceutically acceptable derivatives as the active ingredient, along with various excipients and additives. The suspension is free of xanthan gum and/or polyoxyethylene stearate.
The dosage form is formulated as a liquid oral suspension, allowing for easy administration. It contains a suspending agent, such as carboxymethylcellulose or microcrystalline cellulose, to maintain the uniform distribution of the active ingredient. A surfactant, such as poloxamer or polyoxyethylene sorbitan fatty acid ester, is included to enhance the solubility and stability of the suspension.
Preservatives, such as parabens and their salts, are added to prevent microbial growth. pH adjusting agents, such as citric acid or citrate buffer, are included to maintain the desired pH range of 3.5 to 5.5. Sweetening and flavoring agents are also present to improve the taste and palatability of the suspension.
The dosage form is prepared using a pharmaceutically acceptable liquid carrier, which consists of glycerin and water. The patent specifies the concentration ranges for each component, including the active ingredient, suspending agent, surfactant, and preservatives. The viscosity of the suspension is also defined to be between 700 and 1200 cps.
The patent also describes a kit that includes the immediate release suspension dosage form, along with a dispensing and/or dosing syringe or a measuring cup for accurate administration. Optional instructions for preparation and use may also be included in the kit.
The patent further discloses alternative formulations of the immediate release suspension dosage form, including variations in the concentration of the active ingredient, suspending agent, and surfactant. The particle size distribution of the active ingredient is also specified to be between 5 µm and 200 µm.
Finally, the patent claims methods of treating partial onset seizures in patients by administering the immediate release suspension dosage form. These methods utilize the dosage forms described in the patent, providing a convenient and effective treatment option for patients with this medical condition.
To know more about GlobalData’s detailed insights on Jubilant Pharmova, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
